Literature DB >> 16890256

Changes in Wuchereria bancrofti infection in a highly endemic community following 10 rounds of mass administration of diethylcarbamazine.

K D Ramaiah1, P Vanamail, P K Das.   

Abstract

Mass drug administration (MDA) is the principal strategy of the programme to eliminate lymphatic filariasis (LF). Evaluation of MDA in highly endemic 'sentinel' communities is necessary to understand its impact on LF infection. This study examined the changes in Wuchereria bancrofti infection following 10 rounds of annual mass administration of diethylcarbamazine (DEC) in a highly endemic community. The mean number of DEC treatments received per adult in the community was 7.4+/-2.0. Following 10 rounds of DEC administration, the number of microfilaria (mf) carriers fell from 565 to 55. None of the pre-MDA amicrofilaraemic individuals showed circulating filarial antigen (CFA). However, 54.5% of the pre-MDA microfilaraemic individuals were positive for CFA. All the pre-MDA high intensity mf carriers continued to be positive for CFA, and some of them also showed blood mf. These patients are the most difficult to be cured by MDA and were distributed in 8.2% of the households. All the children born during the last 7 years of the MDA programme were negative for CFA. The study suggests that six to seven DEC treatments per individual suppresses microfilaraemia, except in some people with heavy infection, and repeated MDA has very good potential to prevent infection in children.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16890256     DOI: 10.1016/j.trstmh.2006.05.007

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  4 in total

Review 1.  Diurnally subperiodic filariasis in India-prospects of elimination: precept to action?

Authors:  A N Shriram; K Krishnamoorthy; B P Saha; Avijit Roy; V Kumaraswami; W A Shah; P Jambulingam; P Vijayachari
Journal:  Parasitol Res       Date:  2011-02-01       Impact factor: 2.289

2.  Determinants of success in national programs to eliminate lymphatic filariasis: a perspective identifying essential elements and research needs.

Authors:  Dominique Kyelem; Gautam Biswas; Moses J Bockarie; Mark H Bradley; Maged El-Setouhy; Peter U Fischer; Ralph H Henderson; James W Kazura; Patrick J Lammie; Sammy M Njenga; Eric A Ottesen; Kapa D Ramaiah; Frank O Richards; Gary J Weil; Steven A Williams
Journal:  Am J Trop Med Hyg       Date:  2008-10       Impact factor: 2.345

3.  Efficacy and tolerability of treatment with single doses of diethylcarbamazine (DEC) and DEC plus albendazole (ABZ) for three consecutive years in lymphatic filariasis: a field study in India.

Authors:  Nilima A Kshirsagar; N J Gogtay; B S Garg; P R Deshmukh; D D Rajgor; V S Kadam; P A Thakur; A Gupta; N S Ingole; J K Lazdins-Helds
Journal:  Parasitol Res       Date:  2017-08-07       Impact factor: 2.289

4.  Quantifying the value of surveillance data for improving model predictions of lymphatic filariasis elimination.

Authors:  Edwin Michael; Swarnali Sharma; Morgan E Smith; Panayiota Touloupou; Federica Giardina; Joaquin M Prada; Wilma A Stolk; Deirdre Hollingsworth; Sake J de Vlas
Journal:  PLoS Negl Trop Dis       Date:  2018-10-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.